Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16504412 | 0.70 | CFTR (0.40) | OPRM1 | |
| SCHEMBL3547985 | 0.68 | PTGER3 (0.46) | OPRD1ALDH1A1CYP1A2CYP3A4OPRK1 | |
| SCHEMBL16504738 | 0.68 | ASAH1 (0.33) | HTR6HCAR2 | |
| SCHEMBL15013630 | 0.67 | NPSR1 (0.45) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6601890 | 0.66 | OPRD1 (0.63) | OPRD1OPRK1OPRM1 | |
| SCHEMBL16504440 | 0.65 | HTR6 (0.33) | HTR6HCAR2 | |
| SCHEMBL16504560 | 0.65 | HCAR3 (0.31) | HCAR2 | |
| SCHEMBL15012260 | 0.65 | HCAR3 (0.31) | HTR6HCAR2 | |
| SCHEMBL15012334 | 0.64 | DRD1 (0.36) | OPRD1OPRK1DRD1HTR6OPRM1 | |
| SCHEMBL16504744 | 0.64 | L3MBTL1 (0.36) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788359-B1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RES TRIANGLE INST (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9150582-B2 | Composition and method for neuropeptide S receptor (NPSR) antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | NPSR1, TACR1, NPFFR1 | OPRD1 77/4885ALDH1A1 3727/4885CYP1A2 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.